Keyword: Dewpoint Therapeutics
Dewpoint Therapeutics is teaming up with Bayer on new drugs for a pair of neglected fields: heart disease and women’s health.
The public markets have been receptive to early-stage biotechs but will the IPO remain open? We asked our Fierce 15 winners what they thought.
Dewpoint Therapeutics is on a mission to develop a drug platform that targets biomolecular condensates, an understudied type of organelle found inside cells, and potentially target any and all diseases.